Endece To Present Data On NDC-1308, A Small Molecule With Remyelinating Activity For Treatment Of Secondary Progressive Multiple Sclerosis

MEQUON, Wis.--(BUSINESS WIRE)--ENDECE will present “NDC-1308, a Small Molecule with Remyelinating Activity for Treatment of Secondary Progressive Multiple Sclerosis,” during two sessions of the American Academy of Neurology (AAN) Annual Meeting in Vancouver, Canada, being held April 15-21, 2016. ENDECE was selected to give an oral presentation and their poster (number I10.007) will be presented on Guided Poster Rounds during the Neuroscience Session I10: Remyelination and Repair in Multiple Sclerosis, Tuesday, April 19, 2016 from 1:00-5:30 pm PDT. ENDECE will also present “NDC-1308, a Small Molecule with Remyelinating Activity for Treatment of Secondary Progressive Multiple Sclerosis,” (poster number P3.043) on Monday, April 18, 2016 from 5:30-7:00 pm during Poster Session III P3-090: MS and CNS Inflammatory Disease: Clinical Trials.

“NDC-1308, a Small Molecule with Remyelinating Activity for Treatment of Secondary Progressive Multiple Sclerosis”

At AAN, ENDECE will present efficacy and safety data for NDC-1308, a novel chemical entity discovered by ENDECE, to induce oligodendrocyte progenitor cells (OPCs) to mature into cells that make the myelin sheath (in a manner similar to how the body makes the myelin sheath in healthy individuals). NDC-1308 has a gain-of-function for inducing OPC differentiation for remyelination while being non-estrogenic, non-mutagenic, and non-genotoxic. NDC-1308 is a small molecule that readily crosses the blood-brain barrier, allowing it to reach the tissues in the brain and spinal cord where promoting myelin production is needed.

“We believe that NDC-1308, with its unique mechanism of action, potent remyelinating activity and demonstrated lack of side effects, possesses many desirable attributes of a promising therapy for secondary progressive multiple sclerosis”, commented Steven H. Nye, Ph.D., Vice President of Discovery at ENDECE.

NDC-1308 is being developed for potential use either alone or in combination with current multiple sclerosis (MS) therapies that slow the progression of the disease. Next steps are to complete IND-enabling studies, file the IND, and then initiate Phase 1 human studies.

About ENDECE

ENDECE, LLC (ENDECE), founded in 2006, is a privately held biopharmaceutical drug discovery and development company based in Wisconsin. The company focuses on small-molecule compounds that control key genes within specific signaling pathways as a platform for discovering drugs capable of treating diseases for which there are no cures. ENDECE’s scientists have created a proprietary library of compounds having the potential to treat diseases such as multiple sclerosis (MS) and Alzheimer’s disease.

ENDECE’s business strategy is to discover and develop drug candidates up to or into Phase 1 clinical studies and then secure a licensing partner with expertise in all phases of clinical development and commercialization. ENDECE is led by an experienced management team with a proven ability to take drug candidates from laboratory bench discovery, through clinical studies, and through the FDA approval process to commercial launch.